Psoriatic arthritis therapy advances

Current Opinion in Rheumatology

Volumn 17, Issue 4, 2005, Pages 426-432

  Mease, Philip J ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Biologics; Psoriasis; Psoriatic arthritis; Therapy

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ANTIRHEUMATIC AGENT; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; INTERFERON; LEFLUNOMIDE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ONERCEPT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIBAVIRIN; RITUXIMAB; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS C; HUMAN; INFECTION; LIVER DISEASE; LIVER TOXICITY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TREATMENT INDICATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL RESPONSE MODIFIERS; CONTROLLED CLINICAL TRIALS; HUMANS; RHEUMATOLOGY; TREATMENT OUTCOME;

EID: 23044466416     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000166382.96024.85     Document Type: Review

References (66)

1. Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000; 27:1247-1250.
2. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978; 53:511-518.
3. Brockbank J, Schetag C, Rosen C, et al. Psoriatic arthritis (PSA) is common among patients with psoriasis and family medicine clinic attendees. Arthritis Rheum 2001; 44:394.
4. Salonen S. The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17,900 members of European psoriasis patients associations (poster). In Spring Symposium of the European Academy of Dermatology and Venereology; Malta, 2003.
5. Gelfand J, Gladman D, Mease P, et al. Epidemiology of psoriatic arthritis in the United States population. J Am Acad Dermatol 2005. (in press)
6. Helliwell PS, Wright V. Psoriatic arthritis: clinical features. In: Rheumatology. Volume 2. Klippel J, Dieppe P, editors. St. Louis, MO: CV Mosby; 2000:6.21.21-26.21.28.
7. Mease P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004; 63:755-758. This general review of TNF pathophysiology in psoriasis and PsA and cellular and immunohistochemical impact of TNF inhibition has an excellent bibliography of primary references in the field.
8. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46:1-23; quiz 23-26.
9. Krueger G, Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol 2004; 140:218-225. This is a general review from a dermatologic perspective of the pathophysiologic role of TNF in the skin and joints and the role of TNF inhibition.
10. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113:1664-1675. This is an excellent basic science review of the pathogenesis of psoriasis by key researchers in the field, with explication of the rationale for targeted therapy.
11. Anandarajah AP, Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2004; 16:338-343. This is an excellent review of the pathophysiology of PsA.
12. Kane D, Gogarty M, O'Leary J, et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 2004; 50:3286-3295.
13. Mease PJ. Recent advances in the management of psoriatic arthritis. Curr Opin Rheumatol 2004; 16:366-370.
14. Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol Clin 2004; 22:449-459. This is an excellent review of etanercept therapy in psoriasis and PsA, with a focus on practical management.
15. Gottlieb AB, Antoni CE. Treating psoriatic arthritis: how effective are TNF antagonists? Arthritis Res Ther 2004; 6(Suppl 2):S31-S35.
16. Ruderman EM, Tambar S. Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. Dermatol Clin 2004; 22:477-486. This is an excellent, down-to-earth review of PsA and its diagnosis and treatment.
17. Mease P. Targeting therapy in psoriatic arthritis. Drug Discov Today 2004; 1:389-396.
18. Prasad R, Gladman D. Current and investigational treatment of psoriatic arthritis. Expert Opin Investig Drugs 2004; 13:139-150.
19. Gladman DD. Psoriatic arthritis. Dermatol Ther 2004; 17:350-363. This thorough review of the landscape of therapy of PsA is by an authority in the field.
20. Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151(Suppl 69):3-17.
21. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385-390.
22. Mease P, Kivitz A, Burch F, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50:2264-2272. This is a pivotal study of etanercept therapy in PsA.
23. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996; 39:2013-2020.
24. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157:238-244.
25. Mease P, Ganguly L, Wanke E, et al. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004; 63(Suppl 1): 391. This study establishes 0.3 as the minimal clinically important difference of the HAQ in PsA.
26. Mease P, Ruderman EM, Ritchlin C, et al. Etanercept in psoriatic arthritis: sustained improvement in joint and skin disease and inhibition of radiographic progression at 2 years. Ann Rheum Dis 2004; 63(Suppl 1):99.
27. Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995; 22:241-245.
28. van der Heijde D. Quantification of radiological damage in inflammatory arthritis: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Best Pract Res Clin Rheumatol 2004; 18:847-860. This is a thorough review of the methodology of radiologic assessment in PsA, as well as in RA and ankylosing spondylitis.
29. Mease P, Goffe B, Metz J, et al. Enbrel® (etanercept) in patients with psoriatic arthritis and psoriasis. Ann Rheum Dis 2001; 60(Suppl 1):146.
30. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139:1627-1632; discussion 1632.
31. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-2022.
32. Gottlieb AB. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol Ther 2004; 17:401-408. This is an excellent review of the use of etanercept in psoriasis and PsA.
33. Nanda S, Bathon JM. Etanercept: a clinical review of current and emerging indications. Expert Opin Pharmacother 2004; 5:1175-1186.
34. Mease P, Kavanaugh A, Krueger G, et al. Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: results from IMPACT 2 Trial. Arthritis Rheum 2004; 50(Suppl 9):S616.
35. Antoni C, Kavanaugh A, Kirkham B, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Arthritis Rheum 2002; 46(Suppl 9):S381.
36. Antoni C, Kavanaugh A, Kirkham B, et al. The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Arthritis Rheum 2003; 48(Suppl 9):S265.
37. Antoni C, Kavanaugh A, Kirkham B, et al. The infliximab multinational psoriatic arthritis controlled trial: substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy (IMPACT). Arthritis Rheum 2005, in press.
38. Antoni C, Kavanaugh A, Gladman DD, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Arthritis Rheum 2004; 50(Suppl 9):S450.
39. Kavanaugh A, Krueger G, De Vlam K, et al. Infliximab significantly improves joint and skin involvement in psoriatic arthritis to a substantial extent and irrespective of baseline joint involvement or MTX use: analysis of clinical response from the IMPACT 2 trial. Arthritis Rheum 2004; 50(Suppl 9):S617. This is an abstract regarding the phase III trial of infliximab in PsA.
40. Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004; 63:156-161.
41. Adams AE, Zwicker J, Curiel C, et al. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol 2004; 51:660-662.
42. Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004; 63:769-773. This is a translational study of the histologic and immunohistochemical impact of anti-TNF therapy on skin and synovial tissue.
43. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-center study. Arthritis Res Ther 2004; 6:R326-R334.
44. Canete JD, Pablos JL, Sanmarti R, et al. Antiangiogenic effects of antitumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004; 50:1636-1641.
45. Kruithof E, Baeten D, Van Den Bosch F, et al. Histological evidence that infliximab treatment leads to down regulation of inflammation and tissue remodeling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 2005; 64:529-536 This is a thorough review of the histologic and immunohistochemical effects of anti-TNF therapy in spondyloarthropathies, including PsA, from translational group in Ghent.
46. Ritchlin C, Anandarajaha A, Totterman S, et al. Preliminary data from a study of adalimumab in the treatment of psoriatic arthritis. Ann Rheum Dis 2004; 63(Suppl 1):403.
47. Chew AL, Bennett A, Smith CH, et al. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 2004; 151:492-496.
48. Mease P, Gladman DD, Ritchlin C, et al. Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Arthritis Rheum 2004; 50:4097. This is an abstract on a large controlled trial of adalimumab in PsA.
49. Nikas SN, Drosos AA. Onercept. Serono. Curr Opin Investig Drugs 2003; 4:1369-1376.
50. Hansen K, Cush J, Patel S, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46(Suppl 9):S538.
51. Haraoui B, Keystone EC, Thorne J, et al. The Canadian biologic observational switchover survey (BOSS): switching from infliximab to etanercept leads to successful treatment of rheumatoid arthritis. Ann Rheum Dis 2003; 62(Suppl 1):178.
52. Bombardieri S, Tzioufas AG, McKenna F, et al. Efficacy evaluation of adalimumab (Humira) in patients with single and multiple prior biologies in the ReAct trial. Arthritis Rheum 2004; 50(Suppl 9):S187.
53. Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Arch Dermatol 2004; 140:366.
54. Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62:1078-1082.
55. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42:315-322.
56. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51:580-584.
57. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345:248-255.
58. Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002; 138:591-600.
59. Papp K, Mease P, Garovoy M, et al. Efalizumab in patients with psoriatic arthritis: results of a phase II randomized double-blind placebo controlled study. Presented at International Psoriasis Symposium, Toronto, June 10, 2004.
60. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4lg. N Engl J Med 2003; 349:1907-1915.
61. Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4lg) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192:681-694.
62. McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004; 4:392-397. This paper describes the potential role of inhibition of IL-15 in PsA.
63. Mohren M, Daikeler T, Benz D, et al. Myeloablative immunosuppressive treatment with autologous haematopoietic stem cell transplantation in a patient with psoriatic arthropathy and monoclonal gammopathy of undetermined significance. Ann Rheum Dis 2004; 63:466-467.
64. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 2004; 50:1939-1950. This is a key paper on leflunomide in PsA.
65. Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double-blind, placebo controlled, multi-centre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2004; Nov 4 (Epub ahead of print).
66. Kumar N, Kay LJ, Walker DJ. The treatment of enthesitis in psoriatic arthritis. J Rheumatol 2004; 31:2311-231 2; author reply 231 2-231 3.